VIFOR N chart

Last update: 2022-12-22
Key statistics and financials
Revenue per share 27.94
Dividend & Yield2.00fr (1.12%)
Beta 1.2
Market capitalization 11.52B
Operating cash flow 527.4M
ESG Scores 27.0

Company description

Vifor Pharma AG, a pharmaceutical company, focuses on the development, manufacture, and commercialization of pharmaceutical products in Switzerland, rest of Europe, the United States, and internationally. The company offers Ferinject/Injectafer, a solution of ferric carboxymaltose used for the treatment of iron deficiency and iron deficiency anemia; Maltofer, an oral iron polymaltose complex for infants, children, adolescents, and pregnant woman with iron deficiency; and Mircera, a long-acting erythropoiesis-stimulating agent (ESA) to treat symptomatic anemia associated with the chronic kidney disease (CKD).It also provides Retacrit, a short-acting ESA; Venofer, an intravenous iron sucrose used in the intravenous treatment of iron deficiency; and Velphoro, a non-calcium, iron-based chewable phosphate binder for the treatment of hyperphosphatemia in adults with CKD undergoing dialysis. In addition, the company offers Rayaldee, an orally administered, extended release formulation of calcifediol for the treatment of secondary hyperparathyroidism in patients with CKD; and Veltassa for the treatment of hyperkalemia in CKD and chronic heart failure patients. Further, it develops Vadadustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of altitude on oxygen availability; Avacopan, an orally-administered, highly selective inhibitor of C5aR1 for the treatment of orphan and rare renal diseases;ANG-3777 for the treatment of transplant-associated acute kidney injury; Difelikefalin for the treatment for chronic kidney disease-associated pruritus; and VIT-2763 to treat beta-thalassemia. Vifor Pharma AG has a strategic partnership with Fresenius Kabi and Zeria Pharmaceutical. The company was founded in 1872 and is headquartered in Sankt Gallen, Switzerland. As of August 9, 2022, Vifor Pharma AG operates as a subsidiary of CSL Behring AG.

Sector: Healthcare - Industry: Drug Manufacturers—Specialty & Generic

Financial Ratios
Quick Ratio1.56
Working Capital0.16
Return On Equity0.04
Debt To Equity0.02
Fixed Asset Ratio0.34
Fixed Interest Cover42.17

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities 32.2M -34.1M 39.4M -2.5M
Total Cashflows From Investing Activities -376.1M -132.5M 52.4M -48.8M
Net Borrowings 349.2M -54.5M -23.6M -18.4M
Total Cash From Financing Activities 158.6M -238.5M -268.4M -210.9M
Change To Operating Activities -700k 61.1M -53.6M -24.1M
Issuance Of Stock 3.5M 2.5M 4M 3.2M
Net Income 152.4M 159.1M 359.6M 144.4M
Change In Cash -24.8M 144.6M 185.1M 263.5M
Effect Of Exchange Rate -1.1M -9.3M -22.7M -4.1M
Total Cash From Operating Activities 193.8M 524.8M 423.8M 527.4M
Depreciation 160.5M 206.1M 218.7M 189.3M
Change To Account Receivables -113.1M 40.1M -84.9M 33.9M
Other Cashflows From Financing Activities -45M -45.1M -90.3M -60.1M
Change To Netincome 9.3M 159.8M -44M 195M
Capital Expenditures -62.7M -40.3M -68.5M -57.9M

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 206.4M 212M 193.8M 225.1M
Income Before Tax 269.4M 261M 264.7M 311.7M
Net Income 152.4M 159.1M 359.6M 144.4M
Selling General Administrative 566.7M 573.3M 559.5M 543.9M
Gross Profit 989.8M 1.05B 1.06B 1.14B
Ebit 227.4M 273.6M 313.2M 377.5M
Operating Income 227.4M 273.6M 313.2M 377.5M
Interest Expense -6.8M -9M -7.7M -9M
Income Tax Expense 25M 38.1M 27.1M 46.3M
Total Revenue 1.64B 1.75B 1.76B 1.81B
Cost Of Revenue 648.7M 700.8M 701.2M 671.8M
Total Other Income ExpenseNet 42M -12.6M -48.5M -65.8M
Net Income From Continuing Ops 244.4M 222.9M 237.6M 265.4M
Net Income Applicable To Common Shares 152.4M 159.1M 359.6M 144.4M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 1.13B 1.2B 1.19B 1.13B
Total Stockholder Equity 3.05B 3.32B 3.57B 3.49B
Other Current Liabilities 82.1M 95M 118.7M 137.6M
Total Assets 4.5B 4.93B 5.21B 5.1B
Common Stock 700k 700k 700k 700k
Other Current Assets 2.1M 300k 4M 76M
Retained Earnings 3.25B 3.52B 3.86B 3.75B
Treasury Stock -199.2M -202.4M -293.9M -261M
Cash 400.3M 544.9M 730M 993.6M
Total Current Liabilities 594.4M 541.2M 544M 981.3M
Other Stockholder Equity -180.8M -188.7M -274.9M -251.2M
Property, Plant, and Equipment 269.6M 346.9M 302.3M 186.8M
Total Current Assets 1.25B 1.41B 1.61B 1.88B
Net Tangible Assets 376.1M 733.1M 1.12B 1.1B
Net Receivables 523.3M 479.1M 492.4M 442.7M
Accounts Payable 156.4M 107.9M 162.1M 163.1M


Insider Transactions

Here are the insider transactions of stock shares related to VIFOR N:

Filer Name Transaction Text Ownership Date Filer Relation Shares
NO DATA

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to VIFOR N. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on VIFOR N

Here is the result of two systematic investment strategies applied to VIFOR N. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on VIFOR N

The following chart shows the equity curve of the two systematic investment strategies applied to VIFOR N:

VIFOR N automated entries

The systematic investment strategy that buys the first day of the month would give a performance of -10.97% on the backtest period.

Performance at glance

Performance

-10.97 %

Latent gain

-176.4 fr

Invested capital

1608.6 fr

Annualized return

-2.64 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on VIFOR N

This is the result of two momentum investment strategies applied to VIFOR N. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on VIFOR N

The following chart shows all the entries opened by the momentum investment system on VIFOR N:

VIFOR N momentum entries
  • The first momentum investment strategy would give -10.78% of return on VIFOR N. That represents -446.95fr of latent gain with 4146.8fr of employed capital.
  • The second momentum investment strategy would give -11.84% of return on VIFOR N. That represents -368.65fr of latent gain with 3113.7fr of employed capital.
Performance at glance (1Q Momentum)

Performance

-10.78 %

Latent gain

-446.95 fr

Invested capital

4146.8 fr

Annualized return

-9.51 %
Performance at glance (2Q Momentum)

Performance

-11.84 %

Latent gain

-368.65 fr

Invested capital

3113.7 fr

Annualized return

-3.22 %

Momentum equity curve on VIFOR N

The following chart shows the equity curve of the two momentum strategies applied to VIFOR N:

VIFOR N momentum equity

Note: the dividends potentially given by VIFOR N are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on VIFOR N

The following chart shows the employed capital evolution of the two momentum strategies on VIFOR N since the beginning:

VIFOR N

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250fr, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000fr.


Buy the dip strategy result on VIFOR N

Buy the dip entry openings on VIFOR N

VIFOR N

The performance achieved by the robo-advisor on VIFOR N is -20.54%. That represents -185.1$ of latent gain with 901.2fr of employed capital. The following chart shows VIFOR N stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of VIFOR N, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

-20.54 %

Latent gain

-185.1 fr

Invested capital

901.2 fr

Annualized return

-9.51 %

Equity curve of the strategy applied to VIFOR N

The following chart shows the result of the investment strategy applied to VIFOR N:

VIFOR N

Note: the dividends potentially given by VIFOR N are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on VIFOR N

The following chart shows the employed capital evolution since the beginning of the investment strategy on VIFOR N:

VIFOR N

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on VIFOR N

In this section, I will compare the three previous investment strategies applied to VIFOR N.

Equity curve comparison on VIFOR N

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

VIFOR N investment strategy comparison

Employed capital comparison on VIFOR N

VIFOR N investment comparison

Performance comparison on VIFOR N

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment -10.97% -176.4fr 1608.6fr -2.64%
Momentum 1 quarter -10.78% -446.95fr 4146.8fr -2.75%
Momentum 2 quarters -11.84% -368.65fr 3113.7fr -3.22%
Non-directional -20.54% -185.1fr 901.2fr -9.51%
Annualized return comparison

Automatic investment

-2.64 %

Momentum 1Q

-3.22 %

Momentum 2Q

-3.22 %

Non-directional

-9.51 %

Correlated stocks

Here are the most positively and negatively correlated stocks with VIFOR N:

Positive correlations

Most correlated stocks this year


Most correlated stocks last 3 months

Negative correlation

Most negatively correlated stocks this year


Most negatively correlated stocks last 3 months

Note: The algorithm computes the probability of correlation between VIFOR N and the other stocks. There may be false positives or some missing correlated stocks. If the price of VIFOR N does not vary for 36 weeks, the correlation calculation result will be wrong.


Company information

Company name VIFOR N
Country Switzerland
City Sankt Gallen
Address Rechenstrasse 37
Phone 41 58 851 80 00
Website www.viforpharma.com
FullTime employees 2200
Industry Drug Manufacturers—Specialty & Generic
Sector Healthcare
Exchange XSWX
Ticker VIFN.XSWX
Market www.six-group.com

VIFOR N ESG Scores

Environment scores

Environment ESG Factors Scores
Environment Score 3.3
Peer Environment Performance 2.0330864197531
Environment Percentile unknown
Palm Oil no
Nuclear no
Fur Leather no
GMO no
Coal no
Pesticides no
Animal Testing yes

Social scores

Social ESG Factors Scores
Social Score 16.3
Peer Social Performance 14.299012345679
Social Percentile unknown
Highest Controversy 1
Peer Highest Controversy Performance 1.8780487804878
Adult no
Gambling no
Alcoholic no
Tobacco no
Catholic no
Controversial Weapons no
Small Arms no
Military Contract no
Peer Count yes

Related Controversy: Customer IncidentsSociety & Community Incidents


Governance scores

Governance ESG Factors Scores
Governance Score 7.4
Peer Governance Performance 8.8141975308642
Governance Percentile unknown

ESG at glance
Total ESG Scores: 27.0
Environment Score: 3.3
Social Score: 16.3
Governance Score: 7.4

ESG Performance: AVG_PERF

Peer Group: Pharmaceuticals

Peer Esg Score Performance: 25.306097560976

Rating Year: 2022

Rating Month: 8

Max Age: 86400

Percentile: 52